Affordable Access

deepdyve-link
Publisher Website

The Effect of Mycophenolate Mofetil on Non-Renal Manifestations in Systemic Lupus Erythematosus: Results from Korean Lupus Network Registry.

Authors
  • Jung, Ui Hong1
  • Kwak, Sang Gyu2
  • Choe, Jung Yoon1
  • Lee, Shin Seok3
  • Kim, Seong Kyu4
  • 1 Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea. , (North Korea)
  • 2 Department of Medical Statistics, Catholic University of Daegu School of Medicine, Daegu, Korea. , (North Korea)
  • 3 Department of Rheumatology, Chonnam National University Medical School, Gwangju, Korea. , (North Korea)
  • 4 Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea. [email protected] , (North Korea)
Type
Published Article
Journal
Journal of Korean medical science
Publication Date
Jul 15, 2019
Volume
34
Issue
27
Identifiers
DOI: 10.3346/jkms.2019.34.e185
PMID: 31293110
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The objective of this study was to identify the effects of mycophenolate mofetil (MMF) on non-renal manifestations in systemic lupus erythematosus (SLE). The study population comprised 439 SLE patients from the Korean Lupus Network registry who were followed up annually and completed the baseline survey and two follow-up visits from 2014 to 2018. Disease activity, laboratory markers, and clinical manifestations including mucocutaneous lesions, arthritis, serositis, neurological disorders, and hematologic/immunologic abnormalities were assessed. All variables by group (MMF and non-MMF) effects with time (baseline, 1st follow-up, and 2nd follow-up) were analyzed by generalized estimation equation. Seventy-two patients were treated with MMF. There was significant difference in frequencies of malar rash, arthritis, renal disorder, and hematologic disorder between MMF and non-MMF groups in total SLE patients. In subgroup analysis of hematologic abnormalities in total patients, frequency of leukopenia was significantly different between the two groups during follow-up (P = 0.001), but frequencies of hemolytic anemia, lymphopenia, and thrombocytopenia were not. In addition, frequencies of leukopenia in patients without lupus nephritis were significantly decreased in MMF group compared to non-MMF group (P = 0.012). This study showed that MMF might be a beneficial treatment for hematologic abnormalities, especially leukopenia, in SLE. © 2019 The Korean Academy of Medical Sciences.

Report this publication

Statistics

Seen <100 times